All Cytogenetics Panel

This panel brings together several genetic tests that, taken as a group, give a fairly complete cytogenetic picture of acute lymphoblastic leukemia, or ALL. At diagnosis, the minimum workup for ALL includes bone marrow aspirate for morphology, immunophenotyping, cytogenetics like karyotyping and FISH, and other molecular testing as indicated, and this panel covers that cytogenetic piece in one combined order. It includes a full chromosome analysis, alongside targeted FISH tests for three specific abnormalities, TEL/AML1, BCR-ABL1, and MLL rearrangement, each of which carries its own prognostic weight in ALL. These chromosomal abnormalities are independent prognostic indicators in childhood ALL that directly influence risk-adapted therapy decisions.

Who should get this test done?

This test is recommended for:

●     Individuals newly diagnosed with acute lymphoblastic leukemia, children and adults alike
●     Individuals whose bone marrow morphology suggests ALL but needs genetic confirmation
●     Individuals being risk-stratified to determine intensity of treatment
●     Individuals with ALL whose initial karyotype comes back normal or inconclusive
●     Individuals being evaluated for minimal residual disease after treatment has started
Why consider this test?

The real value of combining these tests into one panel is that no single method catches everything on its own. When standard cytogenetic studies show a normal karyotype, FISH can still detect cryptic rearrangements involving TEL/AML1 that conventional analysis misses entirely, and this happens often enough that relying on karyotyping alone would leave real gaps. Karyotyping, FISH, and PCR each bring their own strengths rather than competing with one another, which is why diagnostic accuracy improves when they’re used together rather than relying on just one method. The specific abnormalities this panel screens for also carry very different prognostic implications, research has shown that patients with TEL-AML1 fusion at diagnosis tend to have meaningfully better overall survival compared to those without it, while BCR-ABL1 and MLL rearrangements generally point toward a tougher disease course needing more aggressive treatment.

More information

A typical multiprobe ALL panel detects abnormalities at specific chromosomal locations, BCR/ABL translocation at 9q34 and 22q11.2, MLL rearrangement at 11q23, and TEL-AML1 fusion involving 12p13 and 21q22, with bone marrow being the usual sample source for all these tests. This kind of panel is particularly useful to order when other major prognostic markers come back negative, since it helps rule out or confirm additional abnormalities that a narrower test might have missed. Results from each component are generally reviewed together rather than separately, giving the treating doctor a single, layered view of the leukemia’s genetic profile.

Other names

●     ALL FISH panel
●     Acute lymphoblastic leukemia cytogenetic workup
●     Leukemia karyotype and FISH panel
●     ALL prognostic cytogenetics panel
●     Combined ALL chromosome analysis panel